Elite Pharmaceuticals ELTP
OTC ELTP
$0.37 +0.05 (+15.63%)
At close: Nov 16, 2026 · 4:00 PM EST

Elite Pharmaceuticals (ELTP) Non Operating Interest Expenses (2009 - 2026)

Updated

Elite Pharmaceuticals' Non Operating Interest Expenses was $69,749 in fiscal Q2 2027 (quarter ended Sep 30, 2026), down 15.4% from $82,470 a year earlier and down 4.6% from the prior quarter.

Analysis

Elite Pharmaceuticals (ELTP) Non Operating Interest Expenses (2009 - 2026) Analysis & Trends

On a trailing twelve-month basis, Elite Pharmaceuticals' Non Operating Interest Expenses was $780,912 through Sep 30, 2026, up 53.8% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $396,664, down 48.6% from FY2025.

  • Non Operating Interest Expenses shows a five-year compound annual growth rate of 8.8% (FY2021 to FY2026).
  • In earlier fiscal years, Non Operating Interest Expenses was $772,367 in FY2025 (+31.2%), $588,622 in FY2024 (-47.1%), $1.11 million in FY2023 (+480.1%) and $191,816 in FY2022 (-26.1%).
  • Quarterly Non Operating Interest Expenses has moved between -$80,204 (fiscal Q3 2026) and $718,264 (fiscal Q4 2026) over five years.
  • Compared with a year earlier, Non Operating Interest Expenses was higher in 1 of the last seven quarters, with growth averaging 8.2%.
  • The best year-over-year quarter for Non Operating Interest Expenses over five years was fiscal Q3 2023 (growth of 762.8%); the worst was fiscal Q2 2026 (a decline of 67.7%).
  • Per Business Quant data, ELTP's Non Operating Interest Expenses in the three fiscal quarters before Q2 2027 was $73,103 (Q1 2027), $718,264 (Q4 2026) and -$80,204 (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 217.00 Mn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn -
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -477.00 Mn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 269.00 Mn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 Elite Pharmaceuticals 401.23 Mn 274.64 Mn 15.99 Mn 69,749.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 69,749.00
Jun 30, 2026 73,103.00
Mar 31, 2026 718,264.00
Dec 31, 2025 -80,204.00
Sep 30, 2025 82,470.00
Jun 30, 2025 158,926.00
Mar 31, 2025 188,843.00
Dec 31, 2024 77,607.00
Sep 30, 2024 255,136.00
Jun 30, 2024 250,781.00
Mar 31, 2024 217,144.00
Dec 31, 2023 121,628.00
Sep 30, 2023 130,438.00
Jun 30, 2023 119,412.00
Mar 31, 2023 330,486.00
Dec 31, 2022 322,681.00
Sep 30, 2022 242,753.00
Jun 30, 2022 216,787.00
Mar 31, 2022 65,440.00
Dec 31, 2021 37,400.00
API Access

Elite Pharmaceuticals Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=ELTP&period=max&api_key=YOUR_API_KEY